Skip to main content

Table 2 Outcomes in published leterature for SBRT for Liver metastasis

From: Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry

Study Number of lesions Number of patients Primary Dose/fractionation Toxicity Median follow Up
(Months)
Local control Survival
Blomgren et al. [24] Variable 31 Mixed 8-66Gy/1–4 2 Hemorrhagic Gastritis 1.5–3.8 80% NR
Herfarth et al. [25] 1–3 37 NR 14–26 Gy/1 NR Mean 14.9 18 m:67% 1 yr.:76%
2 yr.:55%
Hoyer et al. [26] 1–6 (< 6 cm) 44 Mixed Majority CRC 45Gy/3 1 Liver Failure
2 severe late GI
52 2 yr.: 86% 1 yr.:67
2 yr.:38
Mendez Romero et al. [27] 1–3 < 7 cm) 25 Mixed Majority CRC 37.5Gy/3 4 acute Grade ≥ 3
1 late Grade 3
12.9 2 yr.: 86% 1 yr.:85%
2 yr.:62%
Rusthoven et al. [29] 1–3 (< 6 cm) 47 Mixed Majority CRC 60Gy/3 < 2% Late Grade ≥ 3 16 2 yr. 92%
< 3 cm:100%
Median 17.6
Lee et al. [30] Variable 68 Mixed Majority CRC 28-60Gy/3 8 acute Grade 3
1 Grade 4
10.8 1 yr.: 71% 18 m:47%
Ambrosino et al. [37] 1–3 (< 6 cm) 27 Mixed Majority CRC 25-60Gy/3 NR 13 74% NR
Goodman et al. [23] 1–5 (< 5 cm) 26 Mixed Majority CRC 18-30Gy/1 4 late Grade 2 17.3 1 yr.:77% 1 yr.:62%
2 yr.:49%
Rule et al. [31] 1–5 27 Mixed Majority CRC 30Gy/3
50-60Gy/5
No ≥ Grade 2 20 30Gy56%
50Gy:89%
60Gy:100%
30Gy56% 2 yr.
50Gy:67% 2 yr.
60Gy:50% 2 yr
Scorsetti et al. [39] 1–3 (< 6 cm) 61 Mixed Majority CRC 52.5–75/3 No ≥ Grade 3 24 91% 1 yr.: 80%
2 yr.:70%
Present Study Variable 427 Mixed Majority CRC 45(12–60)/3(1–5 NR 14(1–91) Median:52 m
1 yr.: 84%
2 yr.:72%
Median:22 m
1 yr.: 74%
2 yr.:49%